A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Center Hospital East
Baylor College of Medicine
Asan Medical Center
Fudan University
Astellas Pharma Inc
Arcus Biosciences, Inc.
Fudan University
Ono Pharmaceutical Co. Ltd
Massachusetts General Hospital
The First Affiliated Hospital with Nanjing Medical University
I-Mab Biopharma US Limited
Seagen Inc.
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Sichuan University
Xijing Hospital
Nizhny Novgorod Regional Clinical Oncology Center
Dana-Farber Cancer Institute
Leap Therapeutics, Inc.
Fudan University
GERCOR - Multidisciplinary Oncology Cooperative Group
Jazz Pharmaceuticals
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Shandong Cancer Hospital and Institute
Merck Sharp & Dohme LLC
The First Affiliated Hospital of Zhengzhou University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Fudan University
Peking University People's Hospital
The Netherlands Cancer Institute
Fudan University
China Medical University, China
Peking University
Qilu Hospital of Shandong University
Qilu Hospital of Shandong University
Hoffmann-La Roche
Ukrainian Society of Clinical Oncology
BeiGene
First Affiliated Hospital of Zhejiang University
Merck Sharp & Dohme LLC
Sun Yat-sen University
Fudan University
The Netherlands Cancer Institute
Shanghai Henlius Biotech
The First Affiliated Hospital with Nanjing Medical University
Nanfang Hospital, Southern Medical University
University Hospital, Essen
Henan Cancer Hospital
The First Hospital of Jilin University